Why Provectus Biopharmaceuticals (PVCT) Plummeted to a One-Year Low Today (Update)

Update (4:15 p.m.): Updated with Tuesday market close information.

NEW YORK (TheStreet) -- Provectus Biopharmaceuticals  (PVCT) plummeted to a one-year low of 30 cents on Tuesday after the company resumed trading following Friday's halt.

The FDA decided Friday to reject the company's request to grant Breakthrough status to the company's experimental melanoma drug PV-10. The New York Stock Exchange placed Provectus' listing status under review on Tuesday, and the stock resumed trading just before 11 a.m.

For more on this story, read TheStreet's Adam Feuerstein's article here.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock closed down 62.87% to 75 cents. More than 15 million shares changed hands, which easily surpassed the average volume of 788,894. The stock had a range of 30 cents to 87 cents for the day and holds a 52-week range of 30 cents to $6.03.

PVCT Chart

PVCT data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

This Drug Company Loaned Its Now-Fired CEO $2.5M for Made-Up Travel 'Advances'

5 Breakout Stocks Under $10 Set to Soar

Provectus Admits Cash Running Low, Financing Coming Soon

Biotech Stock Mailbag: Vanda, Navidea, Provectus

Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition